RBC Capital Markets Reiterates GBX 170.00 Target On Centamin PLC (LON:CEY), Reiterates “Outperform” Rating; Opgen (OPGN) Shorts Lowered By 16.94%

Opgen Incorporated (NASDAQ:OPGN) had a decrease of 16.94% in short interest. OPGN’s SI was 4.19M shares in January as released by FINRA. Its down 16.94% from 5.04 million shares previously. With 1.09 million avg volume, 4 days are for Opgen Incorporated (NASDAQ:OPGN)’s short sellers to cover OPGN’s short positions. The SI to Opgen Incorporated’s float is 27.3%. The stock increased 1.82% or $0.0034 during the last trading session, reaching $0.1901. About 2.59 million shares traded or 44.36% up from the average. OpGen, Inc. (NASDAQ:OPGN) has declined 38.60% since January 4, 2017 and is downtrending. It has underperformed by 55.30% the S&P500.

RBC Capital Markets have a GBX 170.00 price target on the stock. The price target gives a potential upside of 7.27% from Centamin PLC (LON:CEY)‘s last stock price. This rating was revealed to clients and investors in a note on 4 January.

Among 2 analysts covering OpGen (NASDAQ:OPGN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OpGen has $2.50 highest and $1.0 lowest target. $1.75’s average target is 820.57% above currents $0.1901 stock price. OpGen had 6 analyst reports since June 29, 2016 according to SRatingsIntel. H.C. Wainwright maintained OpGen, Inc. (NASDAQ:OPGN) rating on Tuesday, July 18. H.C. Wainwright has “Buy” rating and $100 target. On Wednesday, June 29 the stock rating was initiated by Rodman & Renshaw with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 8. On Monday, September 11 the stock rating was maintained by H.C. Wainwright with “Buy”. The company was maintained on Wednesday, August 9 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Tuesday, October 24.

OpGen, Inc., a precision medicine company, engages in developing molecular information services and products to combat infectious diseases in the healthcare industry worldwide. The company has market cap of $10.73 million. The firm utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It currently has negative earnings. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Centamin plc, together with its subsidiaries, engages in the exploration, mining, and development of precious metals in Egypt, Burkina Faso, Côte d’Ivoire, United Kingdom, and Australia. The company has market cap of 1.83 billion GBP. The firm explores for gold ore deposits. It has a 18.06 P/E ratio. It primarily holds interest in the Sukari Gold Mine project, which covers an area of 160 square kilometers located in the south-easterly region of the Eastern Desert, Egypt.

Among 14 analysts covering Centamin PLC (LON:CEY), 10 have Buy rating, 2 Sell and 2 Hold. Therefore 71% are positive. Centamin PLC has GBX 215 highest and GBX 50 lowest target. GBX 157.50’s average target is -0.88% below currents GBX 158.9 stock price. Centamin PLC had 110 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Hold” rating by Numis Securities given on Thursday, November 12. The company was maintained on Monday, January 9 by Panmure Gordon. Numis Securities maintained the shares of CEY in report on Thursday, August 13 with “Hold” rating. The stock of Centamin Plc (LON:CEY) earned “Hold” rating by Jefferies on Tuesday, April 18. The stock of Centamin Plc (LON:CEY) earned “Buy” rating by Investec on Friday, September 2. The firm earned “Not Rated” rating on Monday, October 9 by Shore Capital. Jefferies maintained the stock with “Hold” rating in Tuesday, November 1 report. RBC Capital Markets maintained the shares of CEY in report on Friday, September 30 with “Sector Performer” rating. RBC Capital Markets maintained the shares of CEY in report on Thursday, August 11 with “Sector Performer” rating. Macquarie Research maintained it with “Outperform” rating and GBX 120 target in Tuesday, May 17 report.

The stock increased 0.86% or GBX 1.35 during the last trading session, reaching GBX 158.9. About 1.33M shares traded. Centamin Plc (LON:CEY) has 0.00% since January 4, 2017 and is . It has underperformed by 16.70% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: